BGPT: Paper Review: Functional characterization of EMSY gene amplification in human cancers

Explore by Goal

Quick Explanation Copied

Answer (skeptical, evidence-based)

In a cross-cancer panel of 10 EMSY-amplified and 18 non-amplified human cancer cell lines, Wilkerson et al. report that EMSY amplification correlates with EMSY mRNA but does not consistently produce EMSY protein overexpression, EMSY silencing is not selectively lethal, RAD51 foci formation after DNA damage is similar with/without EMSY amplification, and cisplatin and olaparib sensitivities are not increased. Overall, their data argue EMSY amplification is unlikely to be a dominant driver of the 11q13–q14 amplicon’s HR phenotype or a strong biomarker for platinum/PARP-inhibitor sensitivity. ()

Long Explanation

Paper Review: Functional characterization of EMSY gene amplification in human cancers

DOI: 10.1002/path.2944 | Published: 7 July 2011

Core claim tested

The paper tests whether EMSY amplification functionally behaves like a BRCA2-pathway/HR defect, predicting increased sensitivity to platinum salts and PARP inhibitors. ()

Key outcome summary (what the data do, not what we hope)

EMSY mRNA tracks copy-number status overall, but mRNA is not always overexpressed in amplified lines and one amplified-negative copy case shows high mRNA. ()
EMSY protein does not consistently correlate with amplification or mRNA; protein expression is described as bimodal and not aligned with copy-number status. ()
EMSY silencing is not selectively lethal in EMSY-amplified models (including 7 vs 9–10 day assays). ()
HR competency assessed by RAD51 foci formation after IR/cisplatin/olaparib appears similar in EMSY-amplified vs non-amplified lines; BRCA1/2 mutant controls behave as expected. ()
Drug sensitivity: cisplatin SF50 and olaparib SF50 are not higher in EMSY-amplified vs non-amplified models; expected hypersensitivity is observed in BRCA1/2 mutant controls. ()

Figure A — Cisplatin sensitivity (SF50) vs EMSY amplification

Points are reconstructed from the paper’s Table 1 entries for cisplatin SF50 values. ()

Figure B — Olaparib sensitivity (SF50) vs EMSY amplification

The paper reports one olaparib SF50 value as “>100” in Table 1. Here it is mapped to 120 only for plot scaling; the qualitative conclusion (no systematic increase by EMSY amplification) is consistent with the paper’s statistical comparisons. (100" for MDA-MB-175; the authors conclude EMSY amplification is not associated with increased olaparib sensitivity and report Mann–Whitney p=0.86 for amplification vs non-amplification comparisons." url="https://doi.org/10.1002/path.2944" number-citations="1" descriptive-anchor-text="Table 1 olaparib SF50 & conclusion" evidence-strength="strong">)

Table 1 (reconstructed subset) — EMSY amplification, and SF50 phenotypes

Cell line	Tumor site (paper)	EMSY amplified?	cisplatin SF50 (µM)	olaparib SF50 (µM)
BHY	Mouth	Yes	1.87	2.66
MDA-MB-134	Breast	Yes	1.85	10.08
MDA-MB-175	Breast	Yes	15.56	>100
SUM44	Breast	Yes	2.95	0.66
SUM52	Breast	No	1.07	0.26
S68	Breast	Yes	3.74	1.29
TE-15	Oesophagus	Yes	0.30	0.34
OVCAR3	Ovary	No	0.19	0.23
NCI-H1395	Lung	No	1.67	2.23
YAPC	Pancreas	No	5.35	2.15

Reconstructed from Table 1 in the paper for the subset shown in the provided full text. ()

Directed critique (skeptical logic chain)

1) Assay validity: do they measure the right functional intermediate?

They use RAD51 foci formation as a surrogate for HR competency after DSB-inducing DNA damage (IR, cisplatin, olaparib), which is a standard mechanistic proxy in this area (as described in their methods). () Their positive/negative controls appear internally consistent: BRCA1/2 defective lines fail to elicit RAD51 foci while EMSY-amplified vs non-amplified lines show similar RAD51 foci proportions. ()

Blind spot: RAD51 foci is an assay-level readout; HR can be modulated through processes not captured by RAD51 foci magnitude alone, but the paper’s convergent drug-sensitivity results also argue against a major HR defect.

2) Causality test: is EMSY dependency (RNAi) consistent with a driver?

They check knockdown with an anti-EMSY antibody and then evaluate survival after pooled EMSY siRNA (and individual siRNAs in supporting materials). No selective lethality is found in EMSY-amplified lines compared to controls. () This weakens the “EMSY is a dominant oncogenic driver of that phenotype” interpretation.

3) Predictive biomarker claim: do drugs behave as expected?

If EMSY amplification truly caused BRCA2-like HR dysfunction, one expects higher sensitivity (lower SF50) to cisplatin and olaparib in EMSY-amplified models. The paper reports no such enrichment: cisplatin SF50 and olaparib SF50 comparisons are similar across EMSY amplification groups, while BRCA1/2 mutants show significantly lower SF50s. ()

Additional internal check: EMSY silencing does not increase cisplatin SF50 in EMSY-amplified lines; BRCA2 silencing does increase cisplatin sensitivity, indicating the experimental system can detect HR/BRCA2-related changes. ()

Context: why EMSY got proposed in the first place (and how this paper challenges it)

Earlier work suggested EMSY as a prognostic/amplified factor in sporadic breast cancer with implications for BRCA2 pathway linkage and poorer outcomes in subsets. () () Later mechanistic/theoretical synthesis papers discussed EMSY amplification among HR-defect candidates for PARP inhibitor synthetic lethality. () Wilkerson et al. (2011) then perform direct functional testing in cell line models and report a negative result for the proposed HR/platinum/PARP links. ()

Limitations & “what would disprove the paper’s conclusion?”

Paper-acknowledged limitations

The study could not test forced expression of full-length EMSY in lines lacking EMSY amplification because they report forced full-length EMSY expression could not be achieved; only ENT (truncated) forced expression had been described by others, which may not replicate full-length biology. ()
Therapeutic response conclusions are in vitro only, so in vivo tumor microenvironment effects, pharmacodynamics, and clonal evolution are not captured. ()

Mechanistic blind spots (inference boundaries)

Copy-number ≠ function: EMSY amplification may modulate HR under specific replication stress contexts not reproduced here, but the paper also tests multiple stimuli and finds consistent RAD51 and drug-sensitivity outcomes. ()
Protein measurement nuance: they note bimodal protein expression and lack of correlation with amplification; if only a rare sub-subpopulation expresses functional EMSY protein, bulk population assays could dilute signal. The paper’s pooled and panel-level results argue against a dominant effect, but do not exclude conditional/rare mechanisms. ()

What could change the conclusion (falsification targets)

Direct evidence that full-length EMSY overexpression in appropriate genetic backgrounds produces reproducible HR impairment by more direct assays than RAD51 foci alone (and that this translates to platinum/PARP sensitivity) would directly undermine the paper’s inference. ()
In vivo models where EMSY amplification/overexpression is necessary for HR-defective phenotypes and drug response would also challenge the paper. ()

Biological interpretation (with confidence levels)

Main conclusion

Based on convergent evidence—lack of EMSY protein dependency, intact RAD51 foci HR surrogates, and lack of cisplatin/olaparib sensitivity shifts—EMSY amplification does not appear to function as a dominant HR-defect driver or predictive biomarker in the examined cell line settings. ()

Confidence is moderate-to-high for the specific claim tested in vitro in this panel, because they include controls that validate the assay’s ability to detect BRCA1/2-related HR/drug phenotypes. ()

Further BGPT actions (bespoke queries)

Author reviews (BGPT)

Feedback:

Updated: April 16, 2026